<DOC>
	<DOC>NCT00094991</DOC>
	<brief_summary>The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Type 2 diabetes; Serum triglyceride concentration &lt; or = 600 mg/dL; Body mass index &lt; or = 37 kg/m2 Type 1 diabetes; History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months; Congestive heart failure (NYHA Class III and IV); Uncontrolled hypertension; Women of Child Bearing Potential History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Type 2 diabetes</keyword>
</DOC>